359 related articles for article (PubMed ID: 29247737)
1. Crystal and Particle Engineering Strategies for Improving Powder Compression and Flow Properties to Enable Continuous Tablet Manufacturing by Direct Compression.
Chattoraj S; Sun CC
J Pharm Sci; 2018 Apr; 107(4):968-974. PubMed ID: 29247737
[TBL] [Abstract][Full Text] [Related]
2. Particle Engineering for Enabling a Formulation Platform Suitable for Manufacturing Low-Dose Tablets by Direct Compression.
Sun WJ; Aburub A; Sun CC
J Pharm Sci; 2017 Jul; 106(7):1772-1777. PubMed ID: 28322940
[TBL] [Abstract][Full Text] [Related]
3. Particle Engineering of Excipients for Direct Compression: Understanding the Role of Material Properties.
Mangal S; Meiser F; Morton D; Larson I
Curr Pharm Des; 2015; 21(40):5877-89. PubMed ID: 26446468
[TBL] [Abstract][Full Text] [Related]
4. Direct Compression Tablet Containing 99% Active Ingredient-A Tale of Spherical Crystallization.
Chen H; Aburub A; Sun CC
J Pharm Sci; 2019 Apr; 108(4):1396-1400. PubMed ID: 30448523
[TBL] [Abstract][Full Text] [Related]
5. Understanding the Factors That Control the Quality of Mini-Tablet Compression: Flow, Particle Size, and Tooling Dimension.
Zhao J; Yin D; Rowe J; Badawy S; Nikfar F; Pandey P
J Pharm Sci; 2018 Apr; 107(4):1204-1208. PubMed ID: 29233726
[TBL] [Abstract][Full Text] [Related]
6. On-Demand Manufacturing of Direct Compressible Tablets: Can Formulation Be Simplified?
Azad MA; Osorio JG; Wang A; Klee DM; Eccles ME; Grela E; Sloan R; Hammersmith G; Rapp K; Brancazio D; Myerson AS
Pharm Res; 2019 Oct; 36(12):167. PubMed ID: 31650274
[TBL] [Abstract][Full Text] [Related]
7. Continuous Feeding and Blending Demonstration with Co-Processed Drug Substance.
Erdemir D; Gawel J; Yohannes B; Yates P; Tang D; Ha K; Breza B; DiMaso E; Abebe A; Zombek J
J Pharm Sci; 2023 Aug; 112(8):2046-2056. PubMed ID: 36462708
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies.
Schenck L; Erdemir D; Saunders Gorka L; Merritt JM; Marziano I; Ho R; Lee M; Bullard J; Boukerche M; Ferguson S; Florence AJ; Khan SA; Sun CC
Mol Pharm; 2020 Jul; 17(7):2232-2244. PubMed ID: 32392068
[TBL] [Abstract][Full Text] [Related]
9. Improving powder flow properties of a direct compression formulation using a two-step glidant mixing process.
Abe H; Yasui S; Kuwata A; Takeuchi H
Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):647-52. PubMed ID: 19571406
[TBL] [Abstract][Full Text] [Related]
10. Provoking an end-to-end continuous direct compression line with raw materials prone to segregation.
Lakio S; Ervasti T; Tajarobi P; Wikström H; Fransson M; Karttunen AP; Ketolainen J; Folestad S; Abrahmsén-Alami S; Korhonen O
Eur J Pharm Sci; 2017 Nov; 109():514-524. PubMed ID: 28899763
[TBL] [Abstract][Full Text] [Related]
11. Engineered particles demonstrate improved flow properties at elevated drug loadings for direct compression manufacturing.
Trementozzi AN; Leung CY; Osei-Yeboah F; Irdam E; Lin Y; MacPhee JM; Boulas P; Karki SB; Zawaneh PN
Int J Pharm; 2017 May; 523(1):133-141. PubMed ID: 28284921
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the powder properties of lamotrigine by crystal forms.
Kavanagh ON; Wang C; Walker GM; Sun CC
Int J Pharm; 2021 Feb; 595():120274. PubMed ID: 33486026
[TBL] [Abstract][Full Text] [Related]
13. Enabling tablet product development of 5-fluorocytosine through integrated crystal and particle engineering.
Perumalla SR; Sun CC
J Pharm Sci; 2014 Apr; 103(4):1126-32. PubMed ID: 24515970
[TBL] [Abstract][Full Text] [Related]
14. In-line monitoring of the drug content of powder mixtures and tablets by near-infrared spectroscopy during the continuous direct compression tableting process.
Järvinen K; Hoehe W; Järvinen M; Poutiainen S; Juuti M; Borchert S
Eur J Pharm Sci; 2013 Mar; 48(4-5):680-8. PubMed ID: 23313622
[TBL] [Abstract][Full Text] [Related]
15. Improved properties of fine active pharmaceutical ingredient powder blends and tablets at high drug loading via dry particle coating.
Kunnath K; Huang Z; Chen L; Zheng K; Davé R
Int J Pharm; 2018 May; 543(1-2):288-299. PubMed ID: 29625168
[TBL] [Abstract][Full Text] [Related]
16. Systematic development of a high dosage formulation to enable direct compression of a poorly flowing API: A case study.
Schaller BE; Moroney KM; Castro-Dominguez B; Cronin P; Belen-Girona J; Ruane P; Croker DM; Walker GM
Int J Pharm; 2019 Jul; 566():615-630. PubMed ID: 31158454
[TBL] [Abstract][Full Text] [Related]
17. Challenges encountered in the transfer of atorvastatin tablet manufacturing - commercial batch-based production as a basis for small-scale continuous tablet manufacturing tests.
Lyytikäinen J; Kyllönen S; Ervasti T; Komulainen E; Pekarek T; Slunečková J; Leskinen J; Ketolainen J; Kubelka T; Stasiak P; Korhonen O
Int J Pharm; 2023 Nov; 647():123509. PubMed ID: 37832703
[TBL] [Abstract][Full Text] [Related]
18. Analytical method development for powder characterization: Visualization of the critical drug loading affecting the processability of a formulation for direct compression.
Hirschberg C; Sun CC; Rantanen J
J Pharm Biomed Anal; 2016 Sep; 128():462-468. PubMed ID: 27368089
[TBL] [Abstract][Full Text] [Related]
19. Improved blend and tablet properties of fine pharmaceutical powders via dry particle coating.
Huang Z; Scicolone JV; Han X; Davé RN
Int J Pharm; 2015 Jan; 478(2):447-55. PubMed ID: 25475016
[TBL] [Abstract][Full Text] [Related]
20. Improving the Manufacturability of Cohesive and Poorly Compactable API for Direct Compression of Mini-tablets at High Drug Loading via Particle Engineering.
Chen L; Lin Y; Irdam E; Madden N; Osei-Yeboah F
Pharm Res; 2022 Dec; 39(12):3185-3195. PubMed ID: 36319885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
